Study examines the use of a novel suprapubic catheter in suprapubic prostatectomy

	Tweet

It is well known that in addition to urethral catheter associated discomfort, there is an increased risk of ascending urethral infection, inflammation and stricture formation with urethral catheters.

Despite the emergence of a multitude of minimally invasive treatments for BPH, the traditional TURP or suprapubic prostatectomy is still commonly performed. Open prostatectomy offers the advantage of a lower re-treatment rate and more complete removal of the prostate adenoma under direct vision, while it avoids the risk of TUR syndrome.

The post-operative morbidity of the suprapubic prostatectomy includes hemorrhage, clot retention, incontinence, urethral or bladder neck stricture and UTI. Some are related to the use of urethral catheters, such a severe bladder irritation, ascending UTI or epididymoorchitis and urethral stricture formation.

A recent report examines the use of a novel catheter, instead of the traditional urethral catheter, for the post-operative urinary drainage after a suprapubic prostatectomy. The study, by H. Djaladat and colleagues from Tehran Iran, is published in the June 2006 issue of the Journal of Urology.

A total of 146 patients underwent suprapubic prostatectomy for refractory lower urinary tract symptoms or urinary retention. Of the patients, 96 were treated with a novel technique without a urethral catheter but with a specially configured 24 F 3-way suprapubic tube. The tube was placed suprapubically and the end drainage holes were tied off with a silk suture. The balloon was filled within the prostatic fossa after adenoma enucleation and two additional drainage holes were made in the side of the catheter that lies within the bladder to allow for urinary drainage and irrigation. The tube was fixed at the dome of the bladder using a purse string suture to prevent migration. A closed suction drain was placed in the space of Reitzius. Fluid was removed slowly from the novel catheter balloon as the urine cleared. The balloon was completely emptied between 24 and 36 hours and the catheter was removed in 5 to 7 days. The mean balloon fluid volume was 29.5 cc. Post-operative indices were compared between the group using the novel catheter and a group of 48 patients using traditional urethral and suprapubic catheters.

Analysis of the results showed that there was no report of clot retention or significant irritation in the novel catheter group, while 22 (44%) and 19 (38%) in the control group had significant irritative symptoms and at least 1 episode of clot retention. The post-operative decrease in hemoglobin was 0.8 mg/dl in the novel group and 1.9 mg/dl in the control group. There were no reports of epididymoorchitis with the novel catheter but this was identified in 4 (8%) in the control group (p < 0.05). In follow-up at 6 months, all patients underwent cystoscopy. The incidence of membranous urethral strictures was 4.1% in the novel catheter group and 14% in the control group. Four more patients had penile urethral stricture and 3 had bladder neck contractures in the control group. Early incontinence (1 week post-operatively) was also reported in 4% of patients with the novel catheter but in 62% of the control group. It did improve in 95% of patients.

This study suggests improved immediate post-operative morbidity with the use of the novel urinary catheter for use in suprapubic prostatectomy with a decrease in the incidence of urethral stricture disease.

By Michael J. Metro, MD

RELATED STORIES:
Prostate Cancer Risk Among Users of Finasteride and Alpha-Blockers   Should the UK lower the age for prostate cancer detection?   New diagnostic tool for prostate cancer   Prostate cancer therapy not tied to bladder cancer   Prostate cancer cost varies widely by treatment   Low-Income Men More Likely to be Diagnosed with Advanced Prostate Cancers   Researchers find new biomarker for fatal prostate cancer   Guide aims to help men understand prostate cancer   Scientists discover way to block growth of prostate cancer cells   Hormonal Dietary Supplements Might Promote Prostate Cancer Progression   Obesity-linked High Blood Volumes Render PSA Prostate Cancer Test Less Effective   Study shows further benefits of noscapine for prostate cancer   New X-ray approach targets prostate cancer   Gene variants in Japanese prostate cancer patients   Discovery at JGH opens door to new treatments for prostate, brain and skin cancers   Calcium consumption may cause prostate cancer in Chinese   Why African-American Men Are at Higher Risk for Prostate Cancer   Age alone should not be used to determine whether to treat prostate cancer with hormones   Vaccine Injection Targeted in Building a Better ‘Bull’s-Eye’ to Fight Prostate Cancer   Many prostate cancer patients receive improper or ‘mismatched’ therapies   PSA test alone not an ideal predictor of prostate cancer   New type of adult stem cells found in the prostate may be involved in prostate cancer development

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]